The Form 4 filing, an SEC report of an insider's share activity, was filed on November 16, 2026. It lists November 13 as the transaction date for Paul Andrew Moore, Zymeworks' chief scientific officer.
Transaction details
| Transaction | |
|---|---|
| Date of Earliest Transaction | 2026-11-13 |
| Date of Latest Transaction | 2026-11-13 |
| Buy/Sell | sell |
| Transaction Count | 1 |
| Shares Transacted | 25,000 |
| Price | $26.04 |
| Total Transaction Value | $651,000.00 |
| Insider | |
| Ticker Symbol | ZYME |
| Company | Zymeworks Inc. |
| Insider Name | Moore Paul Andrew |
| Insider Title | Chief Scientific Officer |
| Sector - Industry | Healthcare - Biotechnology |
| Holdings | |
| Total Shares Owned After Transaction | 33,756 |
| Position Size Change | 42.55% |
| Filing | |
| Filing Date | 2026-11-16 |
| SEC Link | View filing |
FAQ
What type of transaction is this?
This was a sale of ZYME shares, reported with SEC transaction code S. The transaction information also suggests a link to an exercise or conversion.
An exercise can mean using a stock option, a right to buy shares. A conversion turns another investment into shares.
What was the average price of the transaction?
The average sale price was $26.04 per share for the one reported transaction.
How did this transaction affect the insider's holdings?
Paul Andrew Moore sold 25,000 shares and reported 33,756 shares owned afterward. He sold 42.55% of the shares he owned before the sale.
What's the total transaction value?
The total reported transaction value was $651,000.00. That amount covers the single sale of 25,000 shares.
Are there any special circumstances around this transaction?
The sale may be linked to an exercise or conversion with the same share count. The transaction information identifies a match between a code M share acquisition and this code S sale in the same filing.
Details of the code M acquisition and the filing's footnotes are not available here. Matching share counts alone do not confirm matching dates, share types, or accounts. They also do not show that the shares acquired were the ones sold. The sale's purpose and whether it was required remain unknown.
For research purposes only; not investment advice.